Global pharmaceutical giant , known as in the United States and Canada, has announced a $10 million commitment to the in support of GFF's initiative.
Announced at the in Davos, Switzerland, the commitment was made through the initiative, a ten-year, $500 million program to dramatically reduce the number of women around the world dying from complications of pregnancy and childbirth. Described as the first commitment in support of the initiative from the private sector, the funds will support innovative financing mechanisms and public-private partnerships aimed at scaling high-impact interventions that help women and children survive and thrive through critical periods of life, including birth, their early years, and adolescence.
Through GFF, a multi-stakeholder partnership hosted by the World Bank Group, low- and middle-income countries will work to prevent an estimated 3.8 million maternal deaths, 100 million child deaths, and 21 million stillbirths by 2030. Partners in the effort include the ; the ; ; the ; the ; and the governments of Canada, Norway, Japan, the United Kingdom, and the U.S.
"Women are the cornerstone of a healthy and prosperous world. When a woman survives pregnancy and childbirth, her family, community, and nation thrive," said MSD chairman and CEO Kenneth C. Frazier. "Our partnership with the GFF demonstrates how the private sector can play a unique role in helping to improve maternal and child health worldwide. We look forward to contributing our resources and expertise to the GFF and its partner organizations to work toward the common goal of ending preventable maternal and child deaths."